Welcome to our dedicated page for PALATIN TECHNOLOGIES SEC filings (Ticker: PTN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Palatin Technologies filings document regulatory disclosures for a biopharmaceutical company developing melanocortin receptor-targeted drug candidates. Its 8-K reports and proxy materials cover capital-structure actions, including a 1-for-50 reverse stock split, warrant-share issuance approvals, equity incentive plan matters and listing or trading-status notices for the company’s common stock.
The filing record also includes material-event disclosure on a research collaboration, license and patent assignment agreement with Boehringer Ingelheim for retinal disease programs, annual meeting voting results, advisory executive-compensation votes, corporate governance matters, operating and financial results, and clinical or regulatory disclosures tied to Palatin’s development pipeline.
A holder of PTN common stock filed a Rule 144 notice to sell 565 shares through Charles Schwab on or about 12/24/2025 on the NYSE Amex. The aggregate market value for these shares is reported as $9,460.53, while total common shares outstanding are listed as 1,702,675. The shares to be sold were originally acquired on 03/04/2011 as stock grants from the issuer as equity compensation, with full payment made in the form of equity compensation on the same date.
Palatin Technologies, Inc. filed an amended current report to update the outcome of a governance-related item from its 2025 annual stockholder meeting. Stockholders voted, on an advisory and non-binding basis, to hold future advisory votes on executive compensation every year, consistent with the Board of Directors’ recommendation.
In response, the Board has decided to include an annual advisory vote on the compensation of the company’s named executive officers in its proxy materials each year, until the next required stockholder vote on how often these advisory votes should occur.
Palatin Technologies executive Stephen T. Wills, who serves as Executive VP and CFO/COO, reported the vesting of performance-based equity awards on December 9, 2025 under the company’s 2011 Stock Incentive Plan. He acquired 95, 330, and 345 restricted share units of common stock at a price of $0 per share as certain performance conditions were certified by the Compensation Committee. These restricted share units each represent the right to receive one share of common stock, with the shares to be issued on or before the 60th day following December 9, 2025.
On the same date, Wills also acquired performance-based stock options to buy Palatin common stock: 142 options with a $362.5 exercise price expiring on June 22, 2032, 518 options with a $109.5 exercise price expiring on June 20, 2033, and 495 options with a $91.5 exercise price expiring on June 4, 2034. Following these transactions, he directly beneficially owned 64,053 shares of common stock and 122,913 derivative securities in the form of stock options.
Palatin Technologies, Inc. director equity grant disclosure: A Palatin Technologies director reported receiving two stock option grants on December 9, 2025 under the company’s 2011 Stock Incentive Plan. Each option is a right to buy 2,400 shares of common stock at an exercise price of $21.38 per share, with both grants expiring on December 9, 2035.
One option grant vests on December 9, 2026, but if the director does not serve through December 31, 2026, it is prorated at 1/12 per month from January 31, 2026. The second option grant vests as to 50% on December 9, 2026 and the remaining 50% on December 9, 2027. Following these grants, the director beneficially owns 5,927 derivative securities in the form of stock options, all held directly.
Palatin Technologies, Inc. reported equity compensation changes for its President and CEO, who is also a director, in a Form 4 insider filing. On December 9, 2025, several performance-based restricted stock unit (RSU) awards granted under the 2011 Stock Incentive Plan partially vested after the Compensation Committee certified that a defined performance objective for the 18 months ending December 31, 2025 was achieved at 100% of the target level.
The vesting resulted in accruals of 110, 380, and 395 common shares at a stated price of $0 per share, bringing the reporting person’s beneficial ownership of common stock to 64,698 shares. The company states these shares have not yet been issued but will be delivered on or before the 60th day following December 9, 2025.
On the same date, three tranches of performance-based stock options also vested in part: 163 options at an exercise price of $362.5, 595 options at $109.5, and 568 options at $91.5, each for common stock, with expirations ranging from June 22, 2032 to June 4, 2034. Following these transactions, the reporting person held 123,939 stock options in total.
Palatin Technologies, Inc. reported equity awards to a director in the form of restricted stock units and stock options under its 2011 Stock Incentive Plan. On December 9, 2025, the director received two grants of 1,000 restricted stock units each, at a price of $0 per share, increasing common stock holdings to 14,081 shares held directly after these awards.
The first restricted stock unit grant vests in full on December 9, 2026. The second vests 50% on December 9, 2026 and 50% on December 9, 2027. On the same date, the director was also granted two stock option awards covering 1,200 shares each at an exercise price of $21.38 per share. One option grant vests on December 9, 2026 with proration if board service ends before December 31, 2026, and the other vests 50% on December 9, 2026 and 50% on December 9, 2027.
Palatin Technologies reported a director equity grant for John K.A. Prendergast. On December 9, 2025, he received 2,600 restricted stock units under the 2011 Stock Incentive Plan, split into two grants of 1,300 units each. One grant vests fully on December 9, 2026, and the other vests 50% on December 9, 2026 and 50% on December 9, 2027, each unit representing one share of common stock at no purchase price.
He was also granted 3,200 stock options at an exercise price of $21.38 per share in two blocks of 1,600 options, both expiring on December 9, 2035. One option grant vests on December 9, 2026 with potential monthly proration if service ends before December 31, 2026, while the other vests 50% on December 9, 2026 and 50% on December 9, 2027. Following these transactions, he beneficially owned 15,102 shares of common stock and 27,281 stock options directly.
Janus Henderson Group plc has disclosed a significant ownership position in Palatin Technologies, Inc. common stock. The filing reports beneficial ownership of 170,097 shares, representing 9.99% of Palatin’s common stock, including certain pre-funded and common stock warrants that are exercisable within 60 days but subject to a 9.99% beneficial ownership cap.
The disclosure notes that, because of this cap, an additional 8,562 pre-funded warrants and 182,000 Series J and 182,000 Series K common warrants are not included in the reported figures. A related reporting person, Janus Henderson Biotech Innovation Master Fund Ltd, is shown as beneficially owning 118,196 shares, or 6.6% of the class, with shared voting and dispositive power. The securities are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Palatin.
Palatin Technologies, Inc. reported an insider ownership update for its President and CEO on a Form 4. On November 14, 2025, the executive had shares of common stock withheld by the company to cover employee payroll tax obligations tied to previously granted stock awards. The reported withholding transactions covered 51, 33, 119, and 142 shares from separate vesting grants, at per-share values determined on their respective vesting dates in June 2025. After these tax-withholding transactions, the executive directly beneficially owned 33,113 shares of Palatin common stock.
Palatin Technologies, Inc. reports that NYSE American has determined its common stock is no longer suitable for listing under Section 1003(f)(v) of the NYSE American Company Guide because of the stock’s low selling price, and NYSE American has commenced delisting proceedings. Trading of the common stock on NYSE American was suspended on May 7, 2025. The common stock has traded on the OTCQB Market of the OTC Markets Group, initially under the symbol “PTNT”, then under “PTNTD” beginning August 12, 2025, for a twenty trading day period following a 1-for-50 reverse stock split. Effective September 10, 2025, the common stock again trades on the OTCQB Market under the symbol “PTNT”.